Hirofumi Hirakawa, MD, PhD

Department of Neuropsychiatry, Oita University Faculty of Medicine, Oita, Japan; Corresponding Author: Hirofumi Hirakawa, MD, PhD, Department of Neuropsychiatry, Oita University Faculty of Medicine, Idaigaoka 1-1, Hasama-machi, Yufu City, Oita 879-5593, Japan ([email protected]).

PCC
Treatment Decision-Making Capacity With the MacCAT-T in Schizophrenia
Brief Report

June 1, 2023

This report is a narrative review of the studies on schizophrenia that evaluated both decision-making capacity for treatment with the MacCAT-T and severity of symptoms using a clinical rating...
Hirofumi Hirakawa
JCP
Letter to the Editor

June 16, 2020

This letter comments on the article "Optimizing Treatment Choices to Improve Adherence and Outcomes in Schizophrenia" by Kane and Correll.
Hirofumi Hirakawa, Nobuyoshi Ishii
PCC
Letter to the Editor

September 7, 2017

Negative symptoms cause serious personal, social, and occupational functioning disability in schizophrenia patients. To date, the effect of bright light therapy on negative symptoms has been rarely studied, and...
Hirofumi Hirakawa, Takeshi Terao, Shozo Fujii, et al
PCC
Letter to the Editor

October 15, 2015

Hirofumi Hirakawa, Takeshi Terao, Taiga Ninomiya, et al

Celebrating
85 Years

Read the Journal of Clinical Psychiatry

Subscribe to read
more articles

Subscribe